LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant melanoma drug Keytruda (Merck & Co.’s pembrolizumab).

LaunchTrends: Keytruda measures the impact of this novel agent on the unresectable or metastatic malignant melanoma therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. The report evaluates physicians’ current awareness and perception of Keytruda relative to other currently available therapies for unresectable or metastatic malignant melanoma, current and anticipated use of Keytruda, and promotional activity of Keytruda.

Questions Answered:

  • What is the awareness of and familiarity with Keytruda among medical oncologists?
  • What are the perceived clinical advantages and disadvantages of Keytruda compared with other marketed agents used for treating unresectable or metastatic malignant melanoma?
  • To what extent is Keytruda currently being used by surveyed medical oncologists? Where does Keytruda fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Keytruda?
  •  What promotional messages are being employed by Merck & Co.?

Scope: 

Market covered: United States.

Primary research: 76 medical oncologists; qualitative interviews with 10 respondents.

Indication coverage: Unresectable or metastatic malignant melanoma.

Questions Answered in This Report:

  • What is the awareness of and familiarity with Keytruda among medical oncologists?

  • What are the perceived clinical advantages and disadvantages of Keytruda compared with other marketed agents used for treating unresectable or metastatic malignant melanoma?

  • To what extent is Keytruda currently being used by surveyed medical oncologists? Where does Keytruda fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Keytruda?

  • What promotional messages are being employed by Merck & Co.?

Scope:

Market covered: United States.

Primary research: 76 medical oncologists; qualitative interviews with 10 respondents.

Indication coverage: Unresectable or metastatic malignant melanoma.

Table of contents

  • Malignant Melanoma - Emerging Therapies - Keytruda Launch Tracking (US) Wave 1
    • Key Findings
      • Awareness and Perceptions of Keytruda
      • Keytruda Trial and Use
      • Competitive Landscape and Merck & Co.’s Promotion
    • Benchmarking Keytruda Launch Success vs. Malignant Melanoma and NSCLC Analogues
      • Prescriber and Nonprescriber Profiles
        • Keytruda: Differences Between Prescriber and Nonprescriber Profiles
        • Keytruda: Differences Between Prescriber and Nonprescriber Profiles
      • Keytruda Awareness and Perceptions
        • Unaided and Aided Awareness of Keytruda
          • Aided Awareness of Keytruda
          • Familiarity with Keytruda
          • Level of Familiarity: Prescribers vs. Nonprescribers
          • Awareness of Keytruda’s FDA Indication
          • Awareness of Keytruda’s Approved Setting
          • Qualitative Quote
          • Aware of Keytruda’s Price?
          • Average Price of Keytruda per Month
          • Unaided Awareness of Therapies for Unresectable or Metastatic Melanoma
        • Familiarity with Keytruda
          • Existence of Keytruda Attributes That Medical Oncologists Were Not Aware Of
          • Aided Familiarity with Therapies for Unresectable or Metastatic Melanoma
        • Sources of Familiarity with Keytruda
          • Initial Reaction to and Interest in Keytruda
            • Initial Reaction to Keytruda
            • Interest Level in Keytruda
            • Keytruda Profile Summary
            • Interviewed Medical Oncologists’ Opinions of Keytruda
          • Impressions of Keytruda
            • Risk-Benefit of Keytruda
            • Uniqueness of Keytruda
        • Keytruda Trial and Use
          • Willingness to Prescribe Keytruda
            • Willingness to Prescribe Keytruda for…
          • Number of Patients Currently Receiving Keytruda
            • Keytruda Prescriber vs. Nonprescriber
            • Mean Number of Keytruda Treated Patients (Among Prescribers)
            • First-, Second-, and Third-Line Treatments for BRAF-Mutation-Positive Unresectable or Metastatic Patients
            • First-, Second-, and Third-Line Treatments for BRAF-Mutation-Negative (Wild Type) Unresectable or Metastatic Patients
            • Qualitative Quotes
            • Keytruda-Treated Patient Populations
            • Keytruda Prescribers
            • Patients Still on Keytruda
            • Patients with Dose Withheld
            • Patients Discontinued Keytruda
            • Reasons Patients Discontinued Keytruda
          • Reasons for Not Yet Prescribing Keytruda
            • Reasons for Having Not Yet Prescribed Keytruda
            • Reasons for Choosing Another Agent Over Keytruda for Keytruda- Eligible Patients
          • Anticipated Keytruda Use
            • Agents Most Likely to Be Prescribed to Unresectable or Metastatic Melanoma Patients
            • Agents Most Likely to Be Prescribed Second-Line to BRAF-Mutation-Positive Unresectable or Metastatic Melanoma Patients who have Received Prior Yervoy but Have NOT Received a Prior BRAF Inhibitor
            • Therapy That Keytruda Is Most Likely to Replace
            • Physician Willingness to Prescribe Keytruda for Treatment-naive Unresectable or Metastatic Patients Regardless of BRAF Mutation Status
            • Physician Likelihood of Prescribing Keytruda in the Following Clinical Scenarios
            • Influence of Keytruda’s FDA Approval on Prescribing in Other Oncology Indications Where Keytruda is Being Evaluated in Clinical Trials
            • Patient Inquires About Keytruda in Past Month
            • Qualitative Quotes
            • Medical Oncologists’ Action Based on Specific Keytruda Patient Inquiries
            • Timeline for Prescribing Keytruda Among Nonprescribers Willing to Prescribe
            • Qualitative Quotes
          • Keytruda Performance on Key Attributes
            • Performance of Keytruda in Terms of Important Attributes
            • Performance of Keytruda and Yervoy in Terms of Important Attributes
            • Factors Holding Back the Prescription of Keytruda
        • Effectiveness of Face-to-Face Detailing for Keytruda
          • Keytruda Sales Representative Frequency and Reach
            • Keytruda Sales Rep Detailing Frequency
            • Qualitative Quotes
          • Satisfaction with Keytruda Sales Representative
            • Keytruda Sales Representative Performance
          • Keytruda Message Recall
            • Topics Discussed with the Keytruda Sales Rep
        • Methodology
          • Primary Market Research Methodology
            • Sample Size
            • Significance Testing in This Study
            • Report Abbreviations
          • Physician Demographics
            • U.S. Region of Practice
            • Practice Size: Number of Medical Oncologists per Practice
            • Years in Clinical Practice
            • Number of Patients Treated Per Month
            • Percentage of Patients Treated per Month
            • Percentage of Patients with Unresectable or Metastatic Melanoma
            • Medical Oncologists’ Practice Location
            • Medical Oncologists’ Practice Setting
        • Appendix
          • Primary Market Research
            • Additional Information
              • Melanoma Market Background
              • U.S. Development Milestones for Keytruda
              • Melanoma Market News
              • Study Objectives
              • Do you coordinate dosing schedules and arrange for patients to be dosed at the same time in order to minimize unnecessary drug wastage?
              • Reasons for Not Coordinating Dosing Schedules to Minimize Drug Wastage (n = 4)
              • Qualitative Quotes
              • Difficult and Time Consuming
              • Qualitative Quotes
              • Managed Care Requirements for Prescribing Keytruda
              • Qualitative Quotes
              • Impact of Managed Care on Prescribing Keytruda
              • Restrictions Imposed on the Duration of Keytruda Treatment by Insurance Plans
              • Patient History
              • Preferred Therapy Choices for BRAF-V600E-Mutation-Positive Patient with Aggressive and Symptomatic Disease, Previously Treated with Yervoy
              • Prescribe Keytruda
              • Drivers for Starting Patient on Keytruda
              • Barriers for Starting Patient on Keytruda
              • Change in Therapy Choice According to Severity of Disease Progression
              • Patient History
              • Prescribe Keytruda
              • Drivers for Starting Patient on Keytruda
              • Barriers for Starting Patient on Keytruda
              • Change in Therapy Choice According to Presence of Brain Metastases

        Author(s): Rachel Webster

        Rachel Webster M.Sc., D.Phil., is a senior director in the oncology and biosimilars team at Decision Resources Group, where she manages a team of analysts in producing syndicated primary and secondary market research reports on a wide range of oncology indications. She also provides sales and client support for all oncology products.

        Previously, Dr. Webster was a senior analyst in the oncology group at Decision Resources. Dr. Webster has extensive experience in market forecasting with detailed expertise in cancer immunotherapies, prostate cancer, gastric cancer, and malignant melanoma. Dr Webster is also experienced in conducting primary research with physicians and payers in a wide range of oncology indications across the major pharmaceutical markets. Prior to joining Decision Resources Group, Dr. Webster was a research scientist at Immunocore in the target validation group, where her research focused on identifying target antigens expressed in cancers and autoimmune diseases using a proprietary T-cell receptor (TCR) technology platform, molecular biology and phage display techniques. Dr. Webster obtained her D.Phil., in biochemistry, M.Sc. and M.A (Hons) in biological sciences, from the University of Oxford.


        Related Reports

        Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

        The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/ME...

        View Details

        Malignant Melanoma | Disease Landscape and Forecast | G7 | 2020

        The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche /...

        View Details

        Malignant Melanoma - Epidemiology - Mature Markets

        DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of ma...

        View Details

        Malignant Melanoma - Epidemiology - Extrapolated Worldwide Coverage

        DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key endometrial cancer pati...

        View Details